China Resources Medical Holdings Company Limited

SEHK:1515 Aktierapport

Börsvärde: HK$5.5b

China Resources Medical Holdings Tidigare resultatutveckling

Tidigare kriterier kontrolleras 0/6

China Resources Medical Holdings s intäkter har minskat med en genomsnittlig årlig takt på -3.9%, medan Healthcare -branschen såg intäkter på växande på 8.6% årligen. Intäkterna har varit växande med en genomsnittlig takt på 36.4% per år. China Resources Medical Holdings s avkastning på eget kapital är 4.7% och den har en nettomarginal på 2.9%.

Viktig information

-3.9%

Tillväxttakt i vinsten

-4.1%

Tillväxttakt för EPS

Healthcare Tillväxt i branschen11.3%
Intäkternas tillväxttakt36.4%
Avkastning på eget kapital4.7%
Nettomarginal2.9%
Senaste uppdateringen av resultatet30 Jun 2024

Senaste uppdateringar av tidigare prestationer

We Think You Can Look Beyond China Resources Medical Holdings' (HKG:1515) Lackluster Earnings

May 06
We Think You Can Look Beyond China Resources Medical Holdings' (HKG:1515) Lackluster Earnings

Recent updates

China Resources Medical Holdings (HKG:1515) Has Some Way To Go To Become A Multi-Bagger

Feb 20
China Resources Medical Holdings (HKG:1515) Has Some Way To Go To Become A Multi-Bagger

Returns At China Resources Medical Holdings (HKG:1515) Appear To Be Weighed Down

Nov 14
Returns At China Resources Medical Holdings (HKG:1515) Appear To Be Weighed Down

Market Participants Recognise China Resources Medical Holdings Company Limited's (HKG:1515) Earnings Pushing Shares 34% Higher

Oct 02
Market Participants Recognise China Resources Medical Holdings Company Limited's (HKG:1515) Earnings Pushing Shares 34% Higher

We Think You Can Look Beyond China Resources Medical Holdings' (HKG:1515) Lackluster Earnings

May 06
We Think You Can Look Beyond China Resources Medical Holdings' (HKG:1515) Lackluster Earnings

China Resources Medical Holdings (HKG:1515) Has A Pretty Healthy Balance Sheet

Apr 26
China Resources Medical Holdings (HKG:1515) Has A Pretty Healthy Balance Sheet

Shareholders Should Be Pleased With China Resources Medical Holdings Company Limited's (HKG:1515) Price

Mar 09
Shareholders Should Be Pleased With China Resources Medical Holdings Company Limited's (HKG:1515) Price

Is China Resources Medical Holdings (HKG:1515) Using Too Much Debt?

Nov 29
Is China Resources Medical Holdings (HKG:1515) Using Too Much Debt?

China Resources Medical Holdings' (HKG:1515) Returns Have Hit A Wall

Oct 19
China Resources Medical Holdings' (HKG:1515) Returns Have Hit A Wall

Analyst Forecasts For China Resources Medical Holdings Company Limited (HKG:1515) Are Surging Higher

Aug 30
Analyst Forecasts For China Resources Medical Holdings Company Limited (HKG:1515) Are Surging Higher

Should You Think About Buying China Resources Medical Holdings Company Limited (HKG:1515) Now?

Aug 26
Should You Think About Buying China Resources Medical Holdings Company Limited (HKG:1515) Now?

China Resources Medical Holdings (HKG:1515) Has A Pretty Healthy Balance Sheet

Jun 30
China Resources Medical Holdings (HKG:1515) Has A Pretty Healthy Balance Sheet

China Resources Medical Holdings (HKG:1515) Will Be Hoping To Turn Its Returns On Capital Around

May 12
China Resources Medical Holdings (HKG:1515) Will Be Hoping To Turn Its Returns On Capital Around

Analysts Just Published A Bright New Outlook For China Resources Medical Holdings Company Limited's (HKG:1515)

Apr 03
Analysts Just Published A Bright New Outlook For China Resources Medical Holdings Company Limited's (HKG:1515)

Is It Too Late To Consider Buying China Resources Medical Holdings Company Limited (HKG:1515)?

Feb 21
Is It Too Late To Consider Buying China Resources Medical Holdings Company Limited (HKG:1515)?

China Resources Medical Holdings (HKG:1515) May Have Issues Allocating Its Capital

Jan 10
China Resources Medical Holdings (HKG:1515) May Have Issues Allocating Its Capital

We Think China Resources Medical Holdings (HKG:1515) Can Manage Its Debt With Ease

Nov 30
We Think China Resources Medical Holdings (HKG:1515) Can Manage Its Debt With Ease

Is China Resources Medical Holdings Company Limited (HKG:1515) Trading At A 23% Discount?

Oct 18
Is China Resources Medical Holdings Company Limited (HKG:1515) Trading At A 23% Discount?

China Resources Medical Holdings (HKG:1515) Will Want To Turn Around Its Return Trends

Sep 21
China Resources Medical Holdings (HKG:1515) Will Want To Turn Around Its Return Trends

Are Investors Undervaluing China Resources Medical Holdings Company Limited (HKG:1515) By 47%?

Jul 13
Are Investors Undervaluing China Resources Medical Holdings Company Limited (HKG:1515) By 47%?

Is It Time To Consider Buying China Resources Medical Holdings Company Limited (HKG:1515)?

Jun 24
Is It Time To Consider Buying China Resources Medical Holdings Company Limited (HKG:1515)?

China Resources Medical Holdings (HKG:1515) Is Increasing Its Dividend To HK$0.12

Jun 03
China Resources Medical Holdings (HKG:1515) Is Increasing Its Dividend To HK$0.12

China Resources Medical Holdings (HKG:1515) Will Pay A Larger Dividend Than Last Year At HK$0.12

Apr 27
China Resources Medical Holdings (HKG:1515) Will Pay A Larger Dividend Than Last Year At HK$0.12

We Think China Resources Medical Holdings (HKG:1515) Can Manage Its Debt With Ease

Apr 22
We Think China Resources Medical Holdings (HKG:1515) Can Manage Its Debt With Ease

Growth Investors: Industry Analysts Just Upgraded Their China Resources Medical Holdings Company Limited (HKG:1515) Revenue Forecasts By 45%

Mar 30
Growth Investors: Industry Analysts Just Upgraded Their China Resources Medical Holdings Company Limited (HKG:1515) Revenue Forecasts By 45%

Is Now An Opportune Moment To Examine China Resources Medical Holdings Company Limited (HKG:1515)?

Jan 27
Is Now An Opportune Moment To Examine China Resources Medical Holdings Company Limited (HKG:1515)?

China Resources Medical Holdings Company Limited (HKG:1515) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jan 03
China Resources Medical Holdings Company Limited (HKG:1515) Shares Could Be 37% Below Their Intrinsic Value Estimate

China Resources Medical Holdings (HKG:1515) Will Be Hoping To Turn Its Returns On Capital Around

Nov 19
China Resources Medical Holdings (HKG:1515) Will Be Hoping To Turn Its Returns On Capital Around

Is It Too Late To Consider Buying China Resources Medical Holdings Company Limited (HKG:1515)?

Oct 26
Is It Too Late To Consider Buying China Resources Medical Holdings Company Limited (HKG:1515)?

An Intrinsic Calculation For China Resources Medical Holdings Company Limited (HKG:1515) Suggests It's 44% Undervalued

Sep 20
An Intrinsic Calculation For China Resources Medical Holdings Company Limited (HKG:1515) Suggests It's 44% Undervalued

Here's Why China Resources Medical Holdings (HKG:1515) Can Manage Its Debt Responsibly

Sep 06
Here's Why China Resources Medical Holdings (HKG:1515) Can Manage Its Debt Responsibly

China Resources Medical Holdings (HKG:1515) Might Be Having Difficulty Using Its Capital Effectively

Aug 17
China Resources Medical Holdings (HKG:1515) Might Be Having Difficulty Using Its Capital Effectively

Broker Revenue Forecasts For China Resources Medical Holdings Company Limited (HKG:1515) Are Surging Higher

Jun 21
Broker Revenue Forecasts For China Resources Medical Holdings Company Limited (HKG:1515) Are Surging Higher

China Resources Medical Holdings Company Limited (HKG:1515) Shares Could Be 34% Below Their Intrinsic Value Estimate

Jun 09
China Resources Medical Holdings Company Limited (HKG:1515) Shares Could Be 34% Below Their Intrinsic Value Estimate

Investors Can Find Comfort In China Resources Medical Holdings' (HKG:1515) Earnings Quality

May 03
Investors Can Find Comfort In China Resources Medical Holdings' (HKG:1515) Earnings Quality

China Resources Medical Holdings Company Limited (HKG:1515) Is Yielding 1.4% - But Is It A Buy?

Apr 22
China Resources Medical Holdings Company Limited (HKG:1515) Is Yielding 1.4% - But Is It A Buy?

Fördelning av intäkter och kostnader

Hur China Resources Medical Holdings tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.


Resultat- och intäktshistorik

SEHK:1515 Intäkter, kostnader och resultat (CNY Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
30 Jun 249,9702941,0690
31 Mar 2410,0392761,0610
31 Dec 2310,1082581,0530
30 Sep 239,9583381,0250
30 Jun 239,8094199970
31 Mar 238,8553429310
31 Dec 227,9012668640
30 Sep 226,8913657790
30 Jun 225,8814636950
31 Mar 225,1644416300
31 Dec 214,4474185660
30 Sep 214,0314105040
30 Jun 213,6154024410
31 Mar 213,1833564000
31 Dec 202,7513103580
30 Sep 202,4043133060
30 Jun 202,0583152530
31 Mar 202,0873532530
31 Dec 192,1153912540
30 Sep 192,1124012440
30 Jun 192,1084122350
31 Mar 192,0844212290
31 Dec 182,0594312230
30 Sep 181,9963642250
30 Jun 181,9322982270
31 Mar 181,9053602190
31 Dec 171,8784212120
30 Sep 171,784-4462040
30 Jun 171,690-1,3121960
31 Mar 171,611-1,4101840
31 Dec 161,533-1,5071720
30 Sep 161,504-6561670
30 Jun 161,4751961630
31 Mar 161,4241811560
31 Dec 151,3721671500
30 Sep 151,3372081240
30 Jun 151,302249970
31 Mar 151,254240910
31 Dec 141,206230860
30 Sep 141,090176850
30 Jun 14975122840
31 Mar 14931106790

Kvalitetsintäkter: 1515 har en stor engång förlust av CN¥370.2M {1 månader till 30th June, 2024 1 månader) 30th June, 2024.

Växande vinstmarginal: 1515 s nuvarande netto vinstmarginaler (2.9%) är lägre än förra året (4.3%).


Fritt kassaflöde vs resultatanalys


Analys av tidigare vinsttillväxt

Resultatutveckling: 1515 s intäkter har minskat med 3.9% per år under de senaste 5 åren.

Accelererande tillväxt: 1515 s har haft negativ intäktstillväxt under det senaste året, så det kan inte jämföras med dess 5-åriga genomsnitt.

Resultat vs industri: 1515 hade negativ intäktstillväxt ( -29.8% ) under det senaste året, vilket gör det svårt att jämföra med branschens genomsnitt Healthcare ( -14.3% ).


Avkastning på eget kapital

Hög ROE: 1515 s avkastning på eget kapital ( 4.7% ) anses vara låg.


Avkastning på tillgångar


Avkastning på sysselsatt kapital


Upptäck starka bolag som tidigare presterat bra

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2025/03/12 09:25
Aktiekurs vid dagens slut2025/03/12 00:00
Intäkter2024/06/30
Årlig intjäning2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

China Resources Medical Holdings Company Limited bevakas av 26 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Ling ZhangBNP Paribas Securities (Asia)
Jessica LiBofA Global Research
Yue-Kwong LuiCGS International